Chroma Medicine Announces Data Demonstrating the Benefits of Epigenetic Editing for Multiplex Gene Regulation at ASGCT 2023

Posted on by

Simultaneous epigenetic editing of three genes in primary human T cells resulted in no indels or genomic alterations, while simultaneous triple editing with a Cas9 nuclease generated significant chromosomal abnormalities BOSTON, May 19, 2023 /PRNewswire/ — Chroma Medicine, Inc., (Chroma)…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.